Vaginal Prasterone Versus Estriol in Women With Pelvic Floor Disorders

This prospective, non-randomized comparative study evaluated the effects of short-term vaginal treatment with prasterone or estriol in women with pelvic floor disorders who were awaiting urogynecological surgery. A total of 74 women were included, with 37 participants receiving vaginal prasterone and 37 receiving vaginal estriol. Treatment was administered before surgery for approximately 8 weeks. The study assessed changes in pelvic floor symptoms and quality of life using the WHOQOL-BREF questionnaire and symptom severity scales. The aim was to compare the effects of the two vaginal treatments on symptoms and quality of life before urogynecological surgery.

Inclusion Criteria: * Adult women aged 18 years or older. * Clinically diagnosed pelvic organ prolapse, POP-Q stage II-IV, or stress urinary incontinence, Stamey grade 2-3. * Scheduled for urogynecological surgery. * Received preoperative vaginal treatment with either prasterone or estriol. * Availability of baseline and post-treatment clinical data. * Completed quality-of-life questionnaires. Exclusion Criteria: * Concomitant pelvic organ prolapse and stress urinary incontinence. * Incomplete treatment course. * Missing baseline or post-treatment clinical data. * Incomplete quality-of-life questionnaires.